Aldesleukin Completed Phase 1 Trials for Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01603212Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
NCT00970996Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma